Table 4.
Species | Tumor | Model | Immunologic effect | References |
---|---|---|---|---|
Human | HCC (n = 82) | CD3+ cells, CD56+ cells (treated and distant tumors)↑ | [119] | |
CD68+ cells (treated and distant tumors)↑ | ||||
HCC (n = 10) | ± DC | Phase I study: | [120] | |
CD4+CD25high cells (blood)↓ | ||||
CD8+CD28− cells (blood)↑ | ||||
| ||||
Mouse | HCC | Hepa 1–6 | Activity of tumor-specific CD4+, CD8+ cells (spleen)↑ | [118] |
(C57BL/6) | ±GM-CSF | NK1.1+ cells (spleen)↑ | ||
± CTLA4-mAb | Tumor growth (rechallenge)↓ |